Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
pharmaceuticals: Archive
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
by Zacks Equity Research
Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.
GILDNegative Net Change FGENPositive Net Change ANVSPositive Net Change XLONegative Net Change
biotechnology biotechs medical pharmaceuticals
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
by Zacks Equity Research
Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.
NVSPositive Net Change ANIPNegative Net Change ADMANegative Net Change CALTPositive Net Change
biotechnology pharmaceuticals
Adaptimmune (ADAP) Down on End of Collaboration With Roche
by Zacks Equity Research
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
GSKPositive Net Change RHHBYNegative Net Change PSTXNegative Net Change ADAPNegative Net Change
biotechnology biotechs pharmaceuticals
Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and United Parcel Service, Inc. (UPS).
MSFTNegative Net Change NVONegative Net Change MRKPositive Net Change UPSPositive Net Change BKNGNegative Net Change ELVPositive Net Change
computers pharmaceuticals transportation
Should You Buy Johnson & Johnson (JNJ) Ahead of Earnings?
by Kaibalya Pravo Dey
Johnson & Johnson (JNJ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
JNJNegative Net Change
pharmaceuticals
Beat the Market the Zacks Way: MediaAlpha, NVIDIA, Walmart in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
NVONegative Net Change WMTPositive Net Change PHPositive Net Change ETNNegative Net Change NVDAPositive Net Change TSCOPositive Net Change CLPositive Net Change SENegative Net Change APPNegative Net Change VITLNegative Net Change MAXNegative Net Change
pharmaceuticals retail semiconductor transportation
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
by Zacks Equity Research
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
RHHBYNegative Net Change BMYNegative Net Change ALXOPositive Net Change NRIXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
by Zacks Equity Research
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
NVSPositive Net Change MORPositive Net Change ARVNNegative Net Change
biotechnology medical pharmaceuticals
Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea
by Zacks Equity Research
The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.
REGNNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
by Zacks Equity Research
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
VRTXNegative Net Change CRSPNegative Net Change ALPNPositive Net Change VERANegative Net Change
biotechs gene-therapy medical pharmaceuticals
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
by Zacks Equity Research
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.
AZNPositive Net Change LGNDNegative Net Change ANIPNegative Net Change ADMANegative Net Change
pharmaceuticals
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
by Zacks Equity Research
RallyBio (RLYB) gains 83% after announcing a collaboration deal with J&J to develop novel therapies to reduce the risk of FNAIT in pregnant women, along with funding of $6.6 million from the latter.
JNJNegative Net Change FGENPositive Net Change ANVSPositive Net Change RLYBPositive Net Change
biotechnology biotechs medical pharmaceuticals
Best Momentum Stocks to Buy for April 12th
by Zacks Equity Research
SIGA, SEIC and NTRS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 12, 2024.
NTRSNegative Net Change SEICNegative Net Change SIGANegative Net Change
pharmaceuticals
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
by Zacks Equity Research
Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.
ADMANegative Net Change FGENPositive Net Change ANVSPositive Net Change CADLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
by Kinjel Shah
J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
AZNPositive Net Change JNJNegative Net Change PFENegative Net Change SWAVPositive Net Change
pharmaceuticals
J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?
by Zacks Equity Research
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
JNJNegative Net Change NVAXNegative Net Change PRTANo Net Change FATENegative Net Change
pharmaceuticals
New Strong Buy Stocks for April 12th
by Zacks Equity Research
ZUO, INTZ, SIGA, ENVB and NTRS have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2024.
NTRSNegative Net Change SIGANegative Net Change INTZPositive Net Change ZUONegative Net Change ENVBNegative Net Change
computers pharmaceuticals
Best Value Stocks to Buy for April 12th
by Zacks Equity Research
SIGA and AZZ made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 12, 2024.
AZZNegative Net Change SIGANegative Net Change
pharmaceuticals
Novartis (NVS) to Undertake Job Cuts in Development Department
by Zacks Equity Research
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.
NVSPositive Net Change INCYNegative Net Change MORPositive Net Change
biotechnology biotechs medical pharmaceuticals
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
by Zacks Equity Research
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
RHHBYNegative Net Change BMYNegative Net Change ALXOPositive Net Change NRIXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?
by Zacks Equity Research
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
GSKPositive Net Change PFENegative Net Change BNTXNegative Net Change
pharmaceuticals
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
by Zacks Equity Research
To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
The Zacks Analyst Blog Highlights UnitedHealth, Pfizer, BlackRock, The Hershey and Edison International
by Zacks Equity Research
UnitedHealth, Pfizer, BlackRock, The Hershey and Edison International are part of the Zacks top Analyst Blog.
UNHPositive Net Change PFENegative Net Change EIXPositive Net Change BLKNegative Net Change HSYNegative Net Change
consumer-staples finance medical pharmaceuticals utilities
Top Analyst Reports for UnitedHealth, Pfizer & BlackRock
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including UnitedHealth Group Incorporated (UNH), Pfizer Inc. (PFE) and BlackRock, Inc. (BLK).
UNHPositive Net Change PFENegative Net Change EIXPositive Net Change BLKNegative Net Change HSYNegative Net Change OSKNegative Net Change
finance medical pharmaceuticals
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
by Zacks Equity Research
Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.
BMYNegative Net Change MRNANegative Net Change SYRSPositive Net Change AMLXNegative Net Change
biotechnology biotechs pharmaceuticals